Pathological and molecular features of adrenocortical carcinoma: An update

Journal of Clinical Pathology

Volumn 61, Issue 7, 2008, Pages 787-793

  Volante, M ^a   Buttigliero, C ^a   Greco, E ^a   Berruti, A ^a   Papotti, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROTEIN; PROTEIN P53; SOMATOMEDIN B; TUMOR MARKER;

ADRENAL CORTEX CARCINOMA; ALGORITHM; ALLELIC IMBALANCE; CANCER CELL; CANCER INVASION; CELL INVASION; CHROMOSOME ABERRATION; CHROMOSOME MARKER; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MUTATION; PARAMETER; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; FAMILIAL CANCER; GENETICS; METABOLISM;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ALGORITHMS; CHROMOSOME ABERRATIONS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; NEOPLASTIC SYNDROMES, HEREDITARY; TUMOR MARKERS, BIOLOGICAL;

EID: 47049116905     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.050625     Document Type: Review

References (75)

1. Paton BL, Novitsky YW, Zerey M, ef al. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006;140:914-20.
2. Fulmer BR. Diagnosis and management of adrenal cortical carcinoma. Curr Urol Rep 2007;8:77-82.
3. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 2006;91:14-21.
4. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356: 2372-80.
5. McNicol AM. The adrenal cortex. In: LiVoIsi VA, Asa SL, eds. Endocrine pathology. Philadelphia, PA: Churchill Livingstone, 2002:171-204.
6. Weiss LM, Bertagna X, Chrousos GP, et al. Adrenal cortical carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, eds. World Health Organization classification of tumors, pathology and genetics. Tumors of endocrine organs. Lyon: IARC Press, 2004:139-42.
7. Tang CK, Gray GF. Adrenocortical neoplasms. Prognosis and morphology. Urology 1975;5:691-5.
8. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181-5.
9. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002;26:1612-9.
10. Barnett CC Jr, Varma DG, EI-Naggar AK, et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 2000;128:973-82.
11. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-50.
12. Stojadinovic A, Brennan MF, Hoos A, et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 2003;16:742-51.
13. Hough AJ, Hollifield JW, Page DL, et al. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. Am J Clin Pathol 1979;72:390-9.
14. van Slooten H, Schaberg A, Smeenk D, et al. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985;55:766-73.
15. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-9.
16. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-6.
17. Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am J Surg Pathol 2003;27:867-81.
18. Aiba M, Fujibayashi M. Histopathological diagnosis and prognostic factors in adrenocortical carcinoma. Endocr Pathol 2005;16:13-22.
19. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
20. McNicol AM. Assessment of malignancy in adrenal cortical tumors. Endocr Pathol 2006;17:131-6.
21. Kakimoto S, Yushita Y, Sanefuji T, et al. Non-hormonal adrenocortical adenoma with oncocytoma-like appearances. Hinyokika Kiyo 1986;32:757-63.
22. Sasano H, Suzuki T, Sano T, et al. Adrenocortical oncocytoma. A true nonfunctioning adrenocortical tumor. Am J Surg Pathol 1991;15:949-56.
23. Bisceglia M, Ludovico O, Di Mattia A, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004;12:231-43.
24. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol 2006;17:345-54.
25. Lin BT, Bonsib SM, Mierau GW, et al. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 1998;22:603-14.
26. Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 2002;15:973-8.
27. Karim RZ, Wills EJ, McCarthy SW, et al. Myxoid variant of adrenocortical carcinoma: report of a unique case. Pathol Int 2006;56:89-94.
28. Blanes A, Diaz-Cano SJ. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol 2007;127:398-408
29. Evans HL, Vassilopoulou-Sellin R. Adrenal cortical neoplasms. A study of 56 cases. Am J Clin Pathol 1996;105:76-86.
30. Tauchmanovà L, Colao A, Marzano LA, et al. Andrenocortical carcinomas: twelve-year prospective experience. World J Surg 2004;28:896-903.
31. Assie G, Antoni G, Tissier F, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2007;92:148-54.
32. Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 2002;87:3467-74.
33. Cibas ES, Medeiros LJ, Weinberg DS, et al. Cellular DNA profiles of benign and malignant adrenocortical tumors. Am J Surg Pathol 1990;14:948-55.
34. Medeiros U, Weiss LM. New developments in the pathologic diagnosis of adrenal cortical neoplasms. A review. Am J Clin Pathol 1992;97:73-83.
35. Kjellman M, Kallioniemi OP, Karhu R, et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 1996;56:4219-23.
36. Zhao J, Speel EJ, Muletta-Feurer S, et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol 1999;155:1039-45.
37. Sutter JA, Grimberg A. Adrenocortical tumors and hyperplasias in childhood-etiology, genetics, clinical presentation and therapy. Pediatr Endocrinol Rev 2006;4:32-9.
38. Ljungman M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia 2000;2:208-25.
39. Malkin D. The role of p53 in human cancer. J Neurooncol 2001;51:231-43.
40. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001;98:9330-5.
41. DiGiammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002;9:12-6.
42. Miyamoto H, Kubota Y, Shuin T, et al. Bilateral adrenocortical carcinoma showing loss of heterozygosity at the p53 and RB gene loci. Cancer Genet Cytogenet 1996;88:181-3.
43. Gupta D, Shidham V, Holden J, et al. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol 2001;9:215-21.
44. Pinto EM, Billerbeck AE, Fragoso MC, et al. Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. J Clin Endocrinol Metab 2005;90:2976-81.
45. Sparago A, Cerrato F, Vernucci M, et al. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004;36:958-60.
46. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 2000;183:1-9.
47. Grimberg A. p53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab 2000;70:85-98.
48. Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 1997;82:2559-65.
49. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 2003;162:521-31.
50. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001;61:6762-7.
51. Görtz B, Roth J, Speel EJ, et al. MEN1 gene mutation analysis of sporadic adrenocortical lesions. Int J Cancer 1999;80:373-9.
52. Heppner C, Reincke M, Agarwal SK, et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab 1999;84:216-9.
53. Kjellman M, Roshani L, Teh BT, et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J Clin Endocrinol Metab 1999;84:730-5.
54. Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005;65:7622-7.
55. Pilon C, Pistorello M, Moscon A, et al. Inactivation of the p16 tumor suppressor gene in adrenocortical tumors. J Clin Endocrinol Metab 1999;84:2776-9.
56. Parviainen H, Kiiveri S, Bielinska M, et al. GATA transcription factors in adrenal development and tumors. Mol Cell Endocrinol 2007;265-6:17-22.
57. Vuorenoja S, Rivero-Muller A, Kiiveri S, et al. Adrenocortical tumorigenesis, luteinizing hormone receptor and transcription factors GATA-4 and GATA-6. Mol Cell Endocrinol 2007;269:38-45.
58. deFraipont F, EI Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005;90:1819-29.
59. Velazquez-Fernández D, Laurell C, Geli J, et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005;138:1087-94.
60. West AN, Neale GA, Pounds S, et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res 2007;67:600-8.
61. Goldblum JR, Shannon R, Kaldjian EP, et al. Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. Mod Pathol 1993;6:663-8.
62. Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 2001;57:176-82.
63. Schmitt A, Saremaslani P, Schmid S, et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006;49:298-307.
64. Kamio T, Shigematsu K, Sou H, et al. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990;21:277-82.
65. Edgren M, Eriksson B, Wilander E, et al. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997;17:1303-9.
66. Kiiveri S, Liu J, Arola J, et al. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Mol Cell Endocrinol 2005;233:47-56.
67. Kamio T, Shigematsu K, Kawai K, et al. Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. Am J Pathol 1991;138:83-91.
68. Kjellman M, Enberg U, Höög A, et al. Gelatinase A and membrane-type 1 matrix metalloproteinase mRNA: expressed in adrenocortical cancers but not in adenomas. World J Surg 1999;23:237-42.
69. Kolomecki K, Stepien H, Bartos M, et al. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours. Endocr Regul 2001;35:9-16.
70. Zacharieva S, Atanassova I, Orbetzova M, et al. Circulating vascular endothelial growth factor and active renin concentrations and prostaglandin E2 urinary excretion in patients with adrenal tumours. Eur J Endocrinol 2004;150:345-9.
71. Volante M, Sperone P, Bollito E, et al. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 2006;19:1563-9.
72. Iino K, Sasano H, Yabuki N, et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 1997;10:901-7.
73. Kinoshita H, Ogawa O, Mishina M, et al. Telomerase activity in adrenal cortical tumors and pheochromocytomas with reference to clinicopathologic features. Urol Res 1998;26:29-32.
74. Mannelli M, Gelmini S, Arnaldi G, et al. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. J Clin Endocrinol Metab 2000;85:468-70.
75. Giordano TJ. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr Pathol 2006;17:355-63.